4-furan-2-yl-4-oxo-butyric acid ethyl ester | 54016-69-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 4-furan-2-yl-4-oxo-butyric acid ethyl ester
• 英文别名: 4-[2]furyl-4-oxo-butyric acid ethyl ester；4-[2]Furyl-4-oxo-buttersaeure-aethylester；ethyl 4-(furan-2-yl)-4-oxobutyrate；ethyl 4-(2-furyl)-4-oxobutyrate；Ethyl-β--propionat；Ethyl-β--propionat；Ethyl 4-(2-furyl)-4-oxobutanoate；ethyl 4-(furan-2-yl)-4-oxobutanoate
• CAS: 54016-69-2
• 化学式: C₁₀H₁₂O₄
• 分子量: 196.203
• InChiKey: DTLDXAUFLRHRQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-furan-2-yl-4-oxo-butyric acid ethyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-呋喃-2-基-4-氧代丁酸
  参考文献：
  名称：

  The Stereoselective Synthesis of 2-Alkyl .gamma.-Keto Acid and Heterocyclic Ketomethylene Peptide Isostere Core Units Using Chiral Alkylation by 2-Triflyloxy Esters

  摘要：

  A simple and general protocol for the enantioselective preparation of gamma-keto acids and heterocyclic gamma-keto acids which have an alkyl group at C-2 is reported. The alkyl group is introduced by chiral alkylation using a scalemic 2-triflyloxy ester. The alkylation takes place with inversion of configuration and is compatible with a variety of alkyl groups. This methodology is thus well-suited for the preparation of a wide variety of ketomethylene peptide isosteres.

  DOI：

  10.1021/jo00121a031
• 作为产物：
  描述：

  tert-butyl 3-(furan-2-yl)-3-oxopropanoate 在 sodium hydride 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 21.17h， 生成 4-furan-2-yl-4-oxo-butyric acid ethyl ester
  参考文献：
  名称：

  The Stereoselective Synthesis of 2-Alkyl .gamma.-Keto Acid and Heterocyclic Ketomethylene Peptide Isostere Core Units Using Chiral Alkylation by 2-Triflyloxy Esters

  摘要：

  A simple and general protocol for the enantioselective preparation of gamma-keto acids and heterocyclic gamma-keto acids which have an alkyl group at C-2 is reported. The alkyl group is introduced by chiral alkylation using a scalemic 2-triflyloxy ester. The alkylation takes place with inversion of configuration and is compatible with a variety of alkyl groups. This methodology is thus well-suited for the preparation of a wide variety of ketomethylene peptide isosteres.

  DOI：

  10.1021/jo00121a031

文献信息

• Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06251926B1

  公开（公告）日：2001-06-26

  This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

  本发明提供了一种新颖的氧亚氨基烷酸衍生物，该衍生物具有优异的降糖和降脂作用，用于治疗糖尿病、高脂血症、胰岛素不敏感、胰岛素抵抗和葡萄糖耐量受损。
• Polyether-substituted thiazolium ionic liquid catalysts – a thermoregulated phase-separable catalysis system for the Stetter reaction
  作者：Fengli Yu、Ruili Zhang、Congxia Xie、Shitao Yu

  DOI：10.1039/b921796g

  日期：——

  A series of polyether-substituted thiazolium ionic liquids have been synthesized and used as catalysts in the Stetter reaction. The ionic liquids are a thermoregulated phase-separable catalysis (TPSC) system, because they possess the properties of critical solution temperature (CST) and inverse temperature-dependent solubility in toluene–heptane. The results showed that the novel TPSC system exhibits high recycling efficiency, and provides a potential route for a environmentally benign Stetter reaction.

  一系列聚醚取代的噻唑鎓离子液体已被合成并用作Stetter反应的催化剂。这些离子液体是一种热调节相分离催化（TPSC）系统，因为它们具有临界溶液温度（CST）和在甲苯-己烷中逆温度依赖溶解度的特性。结果显示，这种新型TPSC系统具有高回收效率，并为环保的Stetter反应提供了一种潜在的途径。
• The reaction of alkyl 4-hydroxy-2-alkynoates and 4-hydroxy-2-alkyn-1-ones with palladium tributylammonium formate and with tributylamine: Preparation of 1,4-dicarbonyl compounds
  作者：A. Arcadi、S. Cacchi、F. Marinelli、D. Misiti

  DOI：10.1016/s0040-4039(00)80324-x

  日期：1988.1

  Ethyl 4-oxo-2-alkenoates and 1,4-dioxo-2-alkenes are easily prepared by treating ethyl 4-hydroxy-2-alkynoates and 4-hydroxy-2-alkyn-1-ones with n-tributylamine. Treatment of ethyl 4-hydroxy-2-alkynoates and 4-hydroxy-2-alkyn-1-ones with palladium-tributylammonium formate produces ethyl 4-oxo-alkanoates and 1,4-alkandiones in good to high yield through a novel one-pot isomerization/hydrogenation reaction

  通过用正三丁胺处理4-羟基-2-炔基乙酯和4-羟基-2-炔基-1-酮，可以容易地制备4-氧代-2-链烯酸乙酯和1，4-二氧代-2-链烯。用甲酸钯-三丁基铵处理4-羟基-2-链烷酸乙酯和4-羟基-2-炔基-1-酮可通过新颖的单-羟基苯甲酸乙酯生成4-氧代链烷酸乙酯和1,4-链烷酮，收率高至高。锅异构化/氢化反​​应。
• Oxyiminoalkanoic acid derivatives
  申请人：——

  公开号：US20030186985A1

  公开（公告）日：2003-10-02

  To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance. A compound represented by the formula: 1 wherein R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, —CO—, —CH(OH)— or a group represented by —NR 6 — wherein R 6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, —SO—, —SO 2 — or a group represented by —NR 7 — wherein R 7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R 2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R 3 is a hydroxy group, OR 8 (R 8 is an optionally substituted hydrocarbon group.) or NR 9 R 10 (R 9 and R 10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R 9 and R 10 combine together to form a ring); R 4 and R 5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R 4 may form a ring with R 2 ; provided that when R 1 is a ethoxymethyl, a C 1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R 3 is NR 9 R 10 ; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methylpyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.

  提供一种新型的氧亚胺基脂肪酸衍生物，具有优异的降血糖和降血脂作用，并用于预防或治疗糖尿病、高脂血症、胰岛素不敏感、胰岛素抵抗和糖耐量受损。该化合物的结构式为1，其中R1是可选取的取代的碳氢化合物基团或可选取的取代的杂环基团；X是键，-CO-，-CH（OH）-或由-NR6-表示的基团（其中R6是氢原子或可选取的取代的烷基基团）；n是1到3的整数；Y是氧原子、硫原子、-SO-，-SO2-或由-NR7-表示的基团（其中R7是氢原子或可选取的烷基基团）；环A是苯环，可选取具有1到3个附加取代基团；p是1到8的整数；R2是氢原子、可选取的取代的碳氢化合物基团或可选取的取代的杂环基团；q是0到6的整数；m是0或1；R3是羟基、OR8（其中R8是可选取的取代的碳氢化合物基团）或NR9R10（其中R9和R10是相同或不同的基团，选自氢原子、可选取的取代的碳氢化合物基团、可选取的取代的杂环基团或可选取的取代的酰基，或R9和R10结合形成环）；R4和R5是相同或不同的基团，选自氢原子或可选取的取代的碳氢化合物基团，其中R4可以与R2形成环；但当R1为乙氧甲基、C1-3烷基、苯基或对甲氧基苯基且q=m=0时，R3为NR9R10；且不包括O-[2-氯-4-(2-喹啉基甲氧基)苯甲基]肟和[2-氯-4-(2-喹啉基甲氧基)苯甲基]-2-亚氨基丙酸甲酯；或其盐。
• [EN] OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY<br/>[FR] DERIVES D'ACIDE OXYMINOALCANOIQUE AYANT UN EFFET HYPOGLYCEMIQUE ET HYPOLIPIDEMIQUE
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：WO1999058510A1

  公开（公告）日：1999-11-18

  (EN) To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance. A compound represented by formula (a) wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, -CO-, -CH(OH)- or a group represented by -NR6- wherein R6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, -SO-, -SO2- or a group represented by -NR7- wherein R7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R3 is a hydroxy group, OR8 (R8 is an optionally substituted hydrocarbon group) or NR9R10 (R9 and R10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R9 and R10 combine together to form a ring); R4 and R5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R4 may form a ring with R2; provided that when R1 is a ethoxymethyl, a C1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R3 is NR9R10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methyl pyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.(FR) On décrit un composé de la formule (a), ou un sel dudit composé, qui donne un nouveau dérivé d'acide oxyminoalcanoïque ayant un excellent effet hypoglycémique et hypolipidémique, et s'utilise pour la prévention ou le traitement du diabète sucré, de l'hyperlipémie, de l'insensibilité à l'insuline, de la résistance à l'insuline et de l'intolérance au glucose. Dans ladite formule, R1 est un groupe hydrocarbure éventuellement substitué ou un groupe hétérocyclique éventuellement substitué; X est une liaison -CO-, -CH(OH)- ou un groupe représenté par -NR6- (R6 étant un atome d'hydrogène ou un groupe alkyle éventuellement substitué); n est un entier compris entre 1 et 3; Y est un atome d'oxygène, un atome soufre, -SO-, -SO2- ou un groupe représenté par -NR7- (R7 étant un atome d'hydrogène ou un groupe alkyle éventuellement substitué; le noyau A est un noyau benzénique ayant éventuellement un à trois substituants complémentaires; p est un entier compris entre 1 et 8; R2 est un atome d'hydrogène, un groupe hydrocarbure éventuellement substitué ou un groupe hétérocyclique éventuellement substitué; q est un entier compris entre 0 et 6; m est 0 ou 1; R3 est un groupe hydroxy, OR8 (R8 étant un groupe hydrocarbure éventuellement substitué) ou NR9R10 (R9 et R10 étant des groupes identiques ou différents sélectionnés dans le groupe constitué par un atome d'hydrogène, un groupe hydrocarbure éventuellement substitué, un groupe hétérocyclique éventuellement substitué ou groupe acyle éventuellement substitué, ou R9 et R10 forment ensemble un noyau); R4 et R5 sont des groupes identiques ou différents sélectionnés dans le groupe constitué par un atome d'hydrogène ou un groupe hydrocarbure éventuellement substitué (R4 pouvant former un noyau avec R2); à condition que, d'une part, si R1 est éthoxyméthyle, un alkyle C1-3, phényle ou p-méthoxyphényle et que q=m=0, R3 soit NR9R10; et, d'autre part que O-[2-chloro-4-(2-quinolylméthoxy)phénylméthyl]oxime et un pyruvate de méthyle d'acide [2-chloro-4-(2-quinolylméthoxy)phénylméthyl]-2-iminoxypropionique soient exclus.

  提供一种新型的氧亚胺基脂肪酸衍生物，具有优异的降血糖和降血脂作用，可用于预防或治疗糖尿病、高脂血症、胰岛素不敏感、胰岛素抵抗和糖耐量受损。该化合物由公式(a)表示，其中R1是可选取代的碳氢化合物基团或可选取代的杂环基团；X是键合，-CO-，-CH（OH）-或由-NR6-表示的基团，其中R6是氢原子或可选取代的烷基基团；n是1至3的整数；Y是氧原子、硫原子、-SO-，-SO2-或由-NR7-表示的基团，其中R7是氢原子或可选取代的烷基基团；环A是苯环，可选具有1至3个补充取代基团；p是1至8的整数；R2是氢原子、可选取代的碳氢化合物基团或可选取代的杂环基团；q是0至6的整数；m是0或1；R3是羟基、OR8（其中R8是可选取代的碳氢化合物基团）或NR9R10（其中R9和R10是从氢原子、可选取代的碳氢化合物基团、可选取代的杂环基团或可选取代的酰基基团中选择的相同或不同基团，或R9和R10结合形成一个环）；R4和R5是从氢原子或可选取代的碳氢化合物基团中选择的相同或不同基团，其中R4可以与R2形成环；前提是当R1是乙氧甲基、C1-3烷基、苯基或对甲氧基苯基且q=m=0时，R3为NR9R10；并且排除O-[2-氯-4-(2-喹啉基甲氧基)苯甲基]肟和[2-氯-4-(2-喹啉基甲氧基)苯甲基]-2-亚氨基丙酸的甲酯；或其盐。